Overview Raltegravir Kaletra Pharmacokinetics Status: Completed Trial end date: 2007-12-01 Target enrollment: Participant gender: Summary This will be an open-label, 3-period, fixed sequence study in young, healthy, male and female subjects of the pharmacokinetic interaction between raltegravir and Kaletra. Phase: Phase 4 Details Lead Sponsor: Allina Health SystemAllina Hospitals and ClinicsTreatments: LopinavirRaltegravir PotassiumRitonavir